Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An antibiotic that mediates immune destruction of senescent cancer cells.
Casagrande Raffi G, Chen J, Feng X, Chen Z, Lieftink C, Deng S, Mo J, Zeng C, Steur M, Wang J, Bleijerveld OB, Hoekman L, van der Wel N, Wang F, Beijersbergen R, Zheng J, Bernards R, Wang L. Casagrande Raffi G, et al. Among authors: bernards r. Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2417724121. doi: 10.1073/pnas.2417724121. Epub 2024 Dec 18. Proc Natl Acad Sci U S A. 2024. PMID: 39693343
Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.
Shi Y, Cui D, Xia L, Shi D, Jin G, Wang S, Lin Y, Tang X, Chi J, Wang T, Li M, Lv Z, Zheng J, Jia Q, Yang W, Sun Z, Yang F, Feng H, Yuan S, Zhou W, Qin W, Bernards R, Jin H, Zhai B. Shi Y, et al. Among authors: bernards r. Signal Transduct Target Ther. 2024 Dec 9;9(1):359. doi: 10.1038/s41392-024-02085-8. Signal Transduct Target Ther. 2024. PMID: 39653700 Free PMC article. Clinical Trial.
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.
Yang C, Geng H, Yang X, Ji S, Liu Z, Feng H, Li Q, Zhang T, Zhang S, Ma X, Zhu C, Xu N, Xia Y, Li Y, Wang H, Yu C, Du S, Miao B, Xu L, Wang H, Cao Y, Li B, Zhu L, Tang X, Zhang H, Zhu C, Huang Z, Leng C, Hu H, Chen X, Yuan S, Jin G, Bernards R, Sun C, Zheng Q, Qin W, Gao Q, Wang C. Yang C, et al. Among authors: bernards r. Cancer Cell. 2024 Dec 9;42(12):2064-2081.e19. doi: 10.1016/j.ccell.2024.10.008. Epub 2024 Nov 7. Cancer Cell. 2024. PMID: 39515328
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.
Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, Sogari A, Toh TS, Balaban NQ, Batlle E, Bernards R, Garnett MJ, Hangauer M, Leucci E, Marine JC, O'Brien CA, Oren Y, Patton EE, Robert C, Rosenberg SM, Shen S, Bardelli A. Russo M, et al. Among authors: bernards r. Nat Rev Cancer. 2024 Oct;24(10):694-717. doi: 10.1038/s41568-024-00737-z. Epub 2024 Sep 2. Nat Rev Cancer. 2024. PMID: 39223250 Review.
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.
Embaby A, Huijberts SCFA, Wang L, Leite de Oliveira R, Rosing H, Nuijen B, Sanders J, Hofland I, van Steenis C, Kluin RJC, Lieftink C, Smith CG, Blank CU, van Thienen JV, Haanen JBAG, Steeghs N, Opdam FL, Beijnen JH, Huitema ADR, Bernards R, Schellens JHM, Wilgenhof S. Embaby A, et al. Among authors: bernards r. Clin Cancer Res. 2024 Aug 1;30(15):3157-3166. doi: 10.1158/1078-0432.CCR-23-3171. Clin Cancer Res. 2024. PMID: 38739109
338 results